Anthracycline-induced cardiomyopathy

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 12, 2001, Pages 2-7

  Keefe, Deborah L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DAUNORUBICIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; IRON CHELATING AGENT; MITOXANTRONE; RAZOXANE; SPIRONOLACTONE; TROPONIN I; TROPONIN T;

BONE MARROW TRANSPLANTATION; CARDIOMYOPATHY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; DRUG MONITORING; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HUMAN; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; SCINTIANGIOGRAPHY; STEM CELL TRANSPLANTATION; SYMPTOMATOLOGY;

EID: 0034820943     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26431     Document Type: Conference Paper

References (38)

1. Cardiovascular toxicity with cancer chemotherapy
2. Risk factors for doxorubicin-induced congestive heart failure
3. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer
4. Potential cardiotoxicity with mitoxantrone
5. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults
6. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate
7. Prolongation of isovolumetric relaxation time as assessed by doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans
8. Early detection of doxorubicin cardiotoxicity: Interest of doppler echocardiographic analysis of left ventricular filling dynamics
9. Evaluation of anthracycline cardiotoxicity: Prediction ability and functional correlation of endomyocardial biopsy
10. Anthracycline cardiomyopathy monitored by morphologic changes
11. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer
12. Cardioprotection with dexrazoxane for doxorubicin containing therapy in advanced breast cancer
13. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
14. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro
15. The cardiotoxicity of chemotherapeutic drugs
16. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
17. Adriamycin cardiomyopathy risk factors
18. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
19. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
20. Lower incidence of doxorubicin-induced cardiomyopathy by once a week low-dose administration
21. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
22. Cardiac damage in autologous bone marrow transplant patients: An autopsy study. Cardiotoxic pretreatment as a major risk factor
23. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the cardiology committee of the childrens cancer study group
24. Cardiac toxicity 4 to 20 years after completing anthracycline therapy
25. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer
26. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults
27. Cardiac troponin I in patients with hematologic malignancies
28. Cardiac troponin I in pediatrics: Normal values and potential use in the assessment of cardiac injury
29. Circulating cardiac troponin I in severe congestive heart failure
30. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury
31. Review of tests for monitoring doxorubicin-induced cardiomyopathy
32. Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor
33. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma
34. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity
35. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients
36. Doxorubicin-induced cardiomyopathy
37. Anthracycline-induced cardiotoxicity
38. Epidemiology of anthracycline cardiotoxicity in children and adults